Added to YB: 2025-10-15
Pitch date: 2025-10-14
BRKR [bullish]
Bruker Corporation
+21.04%
current return
Author Info
Aurelion Research is a research analyst with a passion for markets, specializing in high‑conviction ideas across shipping, offshore drilling, and thematic equity research. Sign up for the newsletter.
Company Info
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
Market Cap
$6.5B
Pitch Price
$36.57
Price Target
103.00 (+142%)
Dividend
0.47%
EV/EBITDA
15.06
P/E
-178.34
EV/Sales
2.35
Sector
Life Sciences Tools and Services
Category
value
Bruker (BRKR): A Textbook Double Whammy
BRKR: Scientific instruments leader at $36.80 (~$5.35B mkt cap) w/ 70% rev from #1 market positions. Trades at discount despite 15% historical EPS CAGR, 20%+ ROIC, 8% rev growth (5.5% organic). Temporary margin pressure from NanoString/Phenomex/ELITech acquisitions + NIH cuts (<8% rev exposure) + tariffs. Core biz intact: adjusted EBIT margin 18.9% vs reported 15.4%. Mgmt targets 19.7% by 2030 via $100-120M cost cuts. Proteomics (TimsTOF) doubling addressable market. Founder-CEO owns 30%. $103 5yr PT (19x 2030 EPS) = 200% upside, 25% CAGR. Recovery starts 2026.
Read full article (14 min)